Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PHA-665752 + Sonidegib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PHA-665752 | PHA665752|PHA 665752 | MET Inhibitor 59 | PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533, PMID: 29456739). | |
Sonidegib | Odomzo | NVP-LDE225|Erismodedgib|LDE-225 | SMO Inhibitor 16 | Odomzo (sonidegib) is a small molecule inhibitor of SMO, which inhibits proliferation (PMID: 23935925). Odomzo (sonidegib) is FDA approved for use in patients with locally advanced basal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|